The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Further improvements of ide-cel therapy in KarMMa trials
Larry Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX, suggests improvements for ide-cel therapy in the KarMMa trials. Dr. Anderson recommends starting the treatment earlier in the course of therapy when T-cells are possibly more functional. There is not any data as of yet on this recommendation, so results still need to come out but there is hope for earlier intervention being more impactful. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
